Poor Overall Survival In Septa- And Octogenarian Patients After Radical Prostatectomy And Radiotherapy For Prostate Cancer
Main Category: Prostate / Prostate CancerAlso Included In: Urology / Nephrology; Cancer / Oncology; Radiology / Nuclear Medicine
Article Date: 07 Aug 2008 - 1:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
UroToday.com - In the online issue of European Urology, Dr. Claudio Jeldres and a group of international investigators addressed the overall survival of septa- and octogenarians who underwent radical prostatectomy (RP) or radiotherapy (XRT) for prostate cancer (CaP). The Quebec Health Plan database was used to identify 6,183 men treated with RP or XRT for CaP between 1989 and 2000. The database contained no information on tumor stage or grade, PSA levels, or cause-specific mortality. The researchers controlled for the potential effect of CaP-specific mortality by performing an analysis in a subset of individuals who did not receive any secondary therapy.
Of the 6,138 patients age 70 or older, 1,591 (25.7%) underwent RP and 4,592 (74.3%) were treated with XRT. The median actuarial survival for the entire group was 7.4 years. For the RP patients it was 12.1 years, compared to 5.7 years after XRT. Analyses using life tables identified 10-year survival probability at 38.5%. At 10 years after RP overall survival was 59.3% compared to 30.3% after XRT. The data suggested that 10 years after treatment, 83.6% of RP patients and 69.9% of XRT patients were free of secondary therapy. The risk of overall mortality was 2.1-fold higher in XRT treated patients. Androgen-deprivation therapy exerted a protective effect on survival for XRT patients.
They reported that 62.5%, 44%, and 19.1% of RP patients ages 70-74, 75-79, and 80 or older survived beyond 10 years. The percentages for XRT-treated men were 37.9%, 24.8%, and 9.4% respectively.
The investigators concluded that in this study cohort, 40% of patients who underwent RP and 70% of men who underwent XRT would not have had adequate life expectancy to have warranted attempted curative therapy.
Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, Shariat SF, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI
Eur Urol. 2008 Jul;54(1):107-17
10.1016/j.eururo.2007.10.038
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/117483.php>
APA
http://www.medicalnewstoday.com/releases/117483.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




